The Model for End-stage Liver Disease Comes of Age

Clinics in Liver Disease

Volumn 11, Issue 2, 2007, Pages 249-263

  Freeman Jr , Richard B ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC LIVER DISEASE; DISEASE SEVERITY; HEALTH CARE POLICY; HUMAN; LIVER TRANSPLANTATION; ORGAN DONOR; PATIENT CARE; REVIEW; SCORING SYSTEM; SURVIVAL;

CHRONIC DISEASE; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; MODELS, BIOLOGICAL; SEVERITY OF ILLNESS INDEX; TISSUE AND ORGAN PROCUREMENT;

EID: 34250831086     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2007.04.005     Document Type: Review

References (76)

1. Malinchoc M., Kamath P.S., Gordon F.D., et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 31 (2000) 864-871
2. National Organ Transplant Act (NOTA) sections 371-376 of the Public health Service Act, 1984.
3. Freeman R.B., Weisner R.H., Harper A., et al. The new liver allocation system: moving towards evidence-based transplantation policy. Liver Transpl 8 (2002) 851-858
4. Freeman R.B., and Edwards E.B. Liver transplant waiting time does not correlate with waiting list mortality: implications for liver allocation policy. Liver Transplantation 6 (2000) 543-552
5. Freeman R.B., Rohrer R.J., Katz E., et al. Preliminary results of a liver allocation plan using a continuous medical severity score that de-emphasizes waiting time. Liver Transpl 7 (2001) 173-178
6. Wiesner R.H., McDiarmid S.V., Kamath P.S., et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 7 (2001) 567-580
7. Kamath P.S., Wiesner R.H., Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology 33 (2001) 464-470
8. Wiesner R.H., Edwards E.B., Freeman R.B., et al. Model for end stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124 (2003) 91-96
9. Freeman R.B., Wiesner R.H., Harper A., et al. Results of the first year of the new liver allocation plan. Liver Transpl 10 (2004) 7-15
10. The Organ Procurement and Transplantation Network. Available at: http://www.optn.org/PoliciesandBylaws2/policies/docs/policy_9.doc.
11. Mazzaferro V., Regalio E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 (1996) 693-699
12. American Liver Tumor Study Group. A randomized prospective multi-institutional trial of orthotopic liver transplantation or partial hepatic resection with or without adjuvant chemotherapy for hepatocellular carcinoma. Investigators booklet and protocol. Richmond (VA): American Liver Tumor Study Group; 1998.
13. Cheng S.J., Freeman R.B., and Wong J.B. Predicting the probability of progression free survival in patients with small hepatocellular carcinoma. Liver Transpl 8 (2002) 323-328
14. Yao F.Y., Bass N.M., Nikolai B., et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 9 7 (2003) 684-692
15. Llovet J.M., Furster J., and Bruix J. Intention to treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30 (1999) 1434-1440
16. Freeman R.B., Edwards E.B., and Harper A.M. Comparison of liver transplant waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant 6 (2006) 1416-1421
17. Freeman R.B. Mortality risk versus other endpoints: who should come first on the liver transplant waiting list?. Liver Transpl 10 (2004) 675-677
18. Rodriguez-Luna H., Vargas H.E., Moss A., et al. Regional variations in peer reviewed liver allocation under the MELD system. Am J Transplant 5 9 (2005) 2244-2247
19. Voigt M.D., Zimmerman B., Katz D.A., et al. New national liver transplant allocation policy: is the regional review board process fair?. [see comment]. Liver Transpl 10 5 (2004) 666-674
20. Freeman R.B., Gish R.G., Harper A., et al. Model for End-Stage Liver Disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl 12 Suppl 3 (2006) S128-S136
21. Merion R.M., Schaubel D.E., Dykstra D.M., et al. The survival benefit of liver transplantation. Am J Transplant 2 (2005) 307-313
22. Amin M.G., Wolf M.P., Tenbrook M.A., et al. The underutilization of expanded criteria donor grafts for deceased donor liver transplantation under the MELD system: a decision analysis. Liver Transpl 10 (2004) 1468-1475
23. Schaubel D.E., Sima C.S., Goodrich N.P., et al. Survival benefit of liver transplantation by MELD and donor risk index. Am J Transplant 6 Suppl 1 (2006) 95 [WTC abstracts]
24. Merion R.M., Goodrich N.P., Freeman R.B., et al. Impact of a region allocation rule for high MELD/PELD liver transplant candidates. Liver Transpl 12 (2006) C-103 [Ab #412]
25. Huo T.I., Lin H.C., and Lee S.D. Model for end-stage liver disease and organ allocation in liver transplantation: where are we and where should we go?. [Review] [42 refs]. J Chin Med Assoc 69 5 (2006) 193-198
26. Lee Y.M., Fernandez M., Da Costa M., et al. MELD may not be the better system for organ allocation in liver transplantation patients in Singapore. Singapore Med J 47 7 (2006) 592-594
27. Fink M.A., Angus P.W., Gow P.J., et al. Liver transplant recipient selection: MELD vs. clinical judgment. Liver Transpl 11 (2005) 621-626
28. Ruf A.E., Kremers W.K., Chavez L.L., et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. [see comment]. Liver Transpl 11 3 (2005) 336-343
29. Biggins S.W., Rodriguez H.J., Bacchetti P., et al. Serum sodium predicts mortality in patients listed for liver transplantation. [see comment]. Hepatology 41 1 (2005) 32-39
30. Heuman D.M., Abou-Assi S.G., Habib A., et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. [see comment]. Hepatology 40 4 (2004) 802-810
31. Biggins S.W., Kim W.R., Terrault N.A., et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 130 6 (2006) 1652-1660
32. Trotter J.F., Brimhall B., Arjal R., et al. Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) socres for patients listed for liver transplantation. Liver Transpl 10 8 (2004) 995-1000
33. Gerhardt G., Davitt C., and Boblitz D. Hitachi 736 creatinine values falsely low due to elevated bilirubin. Clin Chem 36 (1990) 1115
34. Delanghe J.R., Louagie H.K., De Buyzere M.L., et al. Glomerular filtration rate and creatinine production in adult icteric patients. Clin Chim Acta 224 1 (1994) 33-44
35. Freeman R.B., Harper A., and Edwards E.B. Liver transplantation: outcomes under MELD/PELD. Current Opinion in Organ Transplantation 10 (2005) 90-94
36. Befeler A.S., Palmer D.E., Hoffman M., et al. The safety of intra-abdominal surgery in patients with cirrhosis: model for end-stage liver disease score is superior to Child-Turcotte-Pugh classification in predicting outcome. Arch Surg 140 (2005) 650-654
37. Northup P.G., Wanamaker R.C., Lee V.D., et al. Model for End-Stage Liver Disease (MELD) predicts nontransplant surgical mortality in patients with cirrhosis. Ann Surg 242 2 (2005) 244-251
38. Teh S.H., Christein J., Donohue J., et al. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality. J Gastrointest Surg 9 9 (2005) 1207-1215 [discussion: 1215]
39. Schroeder R.A., Marroquin C.E., Bute B.P., et al. Predictive indices of morbidity and mortality after liver resection. Ann Surg 243 3 (2006) 373-379
40. Chan H.L., Chim A.M., Lau J.T., et al. Evaluation of model for end-stage liver disease for prediction of mortality in decompensated chronic hepatitis B. Am J Gastroenterol 101 7 (2006) 1516-1523
41. Wong G.L., Hui A.Y., Wong V.W., et al. A retrospective study on clinical features and prognostic factors of biopsy-proven primary biliary cirrhosis in Chinese patients. Am J Gastroenterol 100 10 (2005) 2205-2211
42. Huo T.I., Huang Y.H., Lin H.C., et al. Proposal of a modified Cancer of the Liver Italian Program staging system based on the model for end-stage liver disease for patients with hepatocellular carcinoma undergoing loco-regional therapy. Am J Gastroenterol 101 5 (2006) 975-982
43. Yan G., Duan Y., Ruan L., et al. A study on the relationship between ultrasonographic score and clinical score (MELD, CPT) in cirrhosis. Hepatogastroenterology 52 65 (2005) 1329-1333
44. Ripoll C., Banares R., Rincon D., et al. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. Hepatology 42 4 (2005) 793-801
45. Bilaj F., Hyslop W.B., Rivero H., et al. MR imaging findings in autoimmune hepatitis: correlation with clinical staging. Radiology 236 3 (2005) 896-902
46. Sorrell J.H., Zolnikov B.J., Sharma A., et al. Cognitive impairment in people diagnosed with end-stage liver disease evaluated for liver transplantation. Psychiatry Clin Neurosci 60 2 (2006) 174-181
47. Panzera P., Cicco G., Memeo R., et al. MELD predictive value of alterations of brain perfusion during liver transplantation. Transplant Proc 37 6 (2005) 2622-2625
48. Harrod-Kim P., and Waldman D.L. Abnormal portal venous flow at sonography predicts reduced survival after transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol 16 11 (2005) 1459-1464
49. Dias Teixeira M.C., de Fatima Gomes de Sa Ribeiro M., and Strauss E. A new insight into the differences among non-cirrhotic and cirrhotic patients using the liver disease quality of life instrument (LDQOL). Ann Hepatol 4 4 (2005) 264-271
50. du Cheyron D., Bouchet B., Parienti J.J., et al. The attributable mortality of acute renal failure in critically ill patients with liver cirrhosis. Intensive Care Med 31 12 (2005) 1693-1699
51. Terra C., Guevara M., Torre A., et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 129 6 (2005) 1944-1953
52. Everson G.T., Trotter J., Forman L., et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 42 2 (2005) 255-262
53. Huo T.I., Lin H.C., Huang Y.H., et al. The model for end-stage liver disease-based Japan Integrated Scoring system may have a better predictive ability for patients with hepatocellular carcinoma undergoing locoregional therapy. Cancer 107 1 (2006) 141-148
54. Lee K.H., Lee M.K., Sutedja D.S., et al. Outcome from molecular adsorbent recycling system (MARS) liver dialysis following drug-induced liver failure. Liver Int 25 5 (2005) 973-977
55. Kremers W.K., van Ijperen M., Kim R.W., et al. MELD score as a predictor of pre and post transplant survival in OPTN/UNOS status 1 patients. Hepatology 39 (2004) 764-769
56. Saberifiroozi M., Serati A.R., Malekhosseini S.A., et al. Analysis of patients listed for liver transplantation in Shiraz, Iran. Indian J Gastroenterol 25 1 (2006) 11-13
57. Vilatoba M., Eckhoff D.E., and Contreras J.L. [Recipient selection for liver transplantation]. Revista de Investigacion Clinica 57 2 (2005) 244-251 [in Spanish]
58. McCormick A., and Sultan J. Liver transplantation-patient selection and timing. Med J Malaysia 60 Suppl B (2005) 83-87
59. Merion R.M., Wolfe R.A., Dystra D.M., et al. Longitudinal assessment of mortality risk among candidates for liver transplantation. Liver Transpl 9 (2003) 19-21
60. Bambha K., Kim W.R., Kremers W.K., et al. Predicting survival among patients listed for liver transplantation: an assessment of serial MELD measurements. Am J Transplant 4 11 (2004) 1798-1804
61. Giannini E.G., Risso D., Caglieris S., et al. Longitudinal modifications of the MELD score have prognostic meaning in patients with liver cirrhosis. J Clin Gastroenterol 39 10 (2005) 912-914
62. Ragni M.V., Eghtesad B., Schlesinger K.W., et al. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. [see comment]. Liver Transpl 11 11 (2005) 1425-1430
63. Kim W.R., Therneau T.M., Benson J.T., et al. Deaths on the liver transplant waiting list: an analysis of competing risks. Hepatology 43 2 (2006) 345-351
64. Silberhumer G.R., Hetz H., Rasoul-Rockenschaub S., et al. Is MELD score sufficient to predict not only death on waiting list, but also post-transplant survival?. Transplant International 19 (2006) 271-281
65. Adler M., De Gendt E., Vereerstraeten P., et al. Value of the MELD score for the assessment of pre- and post-liver transplantation survival. Transplant Proc 37 6 (2005) 2863-2864
66. Nagler E., Van Vlierberghe H., Colle I., et al. Impact of MELD on short-term and long-term outcome following liver transplantation: a European perspective. Eur J Gastroenterol Hepatol 17 8 (2005) 849-856
67. Habib S., Berk B., Chang C.C., et al. MELD and prediction of post-liver transplantation survival. Liver Transpl 12 3 (2006) 440-447
68. Ekka-Zohar A., Zitser-Gurevich Y., Mandel M., et al. Graft survival and its determinants: a 3 year national experience with liver transplantation in Israel. Isr Med Assoc J 8 6 (2006) 400-405
69. Sumskiene J., Kupcinskas L., Pundzius J., et al. Prognostic factors for short and long-term survival in patients selected for liver transplantation. Medicina (Kaunas) 41 1 (2005) 39-46
70. Brandsaeter B., Friman S., Broome U., et al. Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastroenterol 38 11 (2003) 1176-1183
71. Onaca N., Levy M.F., Ueno T., et al. An outcome comparison between primary liver transplantation and retransplantation based on the pretransplant MELD score. Transplant International 19 4 (2006) 282-287
72. Feng S., Goodrich N.P., Bragg-Gresham J.L., et al. Characteristics associated with liver graft failure: the concept of a donor risk index. Am J Transplant 6 4 (2006) 783-790
73. Avolio A.W., Agnes S., Gasbarrini A., et al. Prognostic value of MELD score and donor quality in liver transplantation: implications for the donor recipient match. Transplant Proc 38 4 (2006) 1059-1062
74. Renz J.F., Kin C., Kinkhabwala M., et al. Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation. Ann Surg 242 4 (2005) 556-563
75. Carmiel-Haggai M., Fiel M.I., Gaddipati H.C., et al. Recurrent hepatitis C after retransplantation: factors affecting graft and patient outcome. Liver Transpl 11 12 (2005) 1567-1573
76. Axelrod D.A., Koffron A.J., Baker T., et al. The economic impact of MELD on liver transplant centers. Am J Transplant 5 9 (2005) 2297-2301